BG Medicine's Q3 Revenues Shoot up 83 Percent, Plans FDA Submissions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today reported an 83 percent jump year over year in third-quarter revenues and progress in its plans to file for regulatory approval of its tests.

The Waltham, Mass.-based company posted $179,000 in revenues for the three months ended Sept. 30, up from $98,000 a year ago, which it attributed to an increase in sales of its galectin-3 test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.